Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Hospira ( HSP) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.3%. By the end of trading, Hospira fell 32 cents (-1%) to $30.59 on average volume. Throughout the day, 1.9 million shares of Hospira exchanged hands as compared to its average daily volume of 2.2 million shares. The stock ranged in price between $30.58-$31.20 after having opened the day at $30.97 as compared to the previous trading day's close of $30.91. Other companies within the Health Care sector that declined today were: Novogen ( NVGN), down 18.8%, Cardium Therapeutics ( CXM), down 9.9%, Oxygen Biotherapeutics ( OXBT), down 9.6%, and Regulus Therapeutics ( RGLS), down 8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products worldwide. Hospira has a market cap of $5.25 billion and is part of the drugs industry. The company has a P/E ratio of 15.8, below the S&P 500 P/E ratio of 17.7. Shares are down 1.1% year to date as of the close of trading on Wednesday. Currently there are no analysts that rate Hospira a buy, two analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Hospira as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow.

On the positive front, Star Scientific ( STSI), up 16.1%, Biostar Pharmaceuticals ( BSPM), up 12.9%, Retractable Technologies ( RVP), up 12.8%, and CEL-SCI Corporation ( CVM), up 10.6%, were all gainers within the health care sector with Alexion Pharmaceuticals ( ALXN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.